🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Alan Russell, CSO, is presenting at the UCL Muscular Dystrophy UK Neuromuscular Translational Research Conference on "An exercise challenge system to define a universal proteomic signature of muscle injury in adult inherited myopathy and its use in a controlled clinical trial setting."

Join us for the third annual Becker Education and Engagement Day (BEED) on September 27! Take part in discussions ranging from Cardiac Care, Exercise, Mental Wellness, Research and more. To learn more about BEED and to pre-register, visit BeckerEducationandEngagement.com

We expect to report our Q1 2025 financial results and recent business highlights on May 8 pre-market open. The results will be available on our website here: investors.edgewisetx.com/financials/qua…

Today we announced Q1 2025 financial results and recent business highlights. The results are available on our website: investors.edgewisetx.com/financials/qua…

We'll be attending the Annual Congress of the Heart Failure Association of the ESC in Serbia! See our presentation on May 18 at 10:58am. We look forward to seeing you there! #HeartFailure2025

Edgewise management will be presenting at the RBC Capital Markets Global Healthcare Conference. Listen to a fireside chat with Kevin Koch and Behrad Derakhshan on Tuesday, May 20, 2025, at 9:00 am ET. Read the full press release here: investors.edgewisetx.com/news/news-deta…

This #ClinicalTrialsDay, we want to thank everyone who has participated in our Edgewise trials. Without you, our work would not be possible. Edgewise is honored to be developing innovative therapies for those living with muscular dystrophies and cardiovascular diseases.

Marilyn Mok recently attended the ASCPT Alexandria conference to present the poster “Pharmacokinetics and pharmacodynamics of EDG-7500, a first-in-class cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy.”

Our management will be presenting at the 46th Annual Goldman Sachs Global Healthcare Conference. Join Kevin Koch, CEO and Behrad Derakhshan, COO for a fireside chat on June 9, 3:20pm ET. Read the press release for more details: investors.edgewisetx.com/news/news-deta…

This #MensHealthMonth, we’re shining light on Becker muscular dystrophy, a genetic muscular disorder that primarily affects men. We’re reminding men everywhere to prioritize their health. To learn more about #BeckerMD, visit: beckermusculardystrophy.com/living-with-be…

We’re proud to be a sponsor of Becker Education & Engagement Day (BEED). Hear from experts in Becker care & research, meet others affected by the rare neuromuscular disorder, & discover patient resources. Learn more: BeckerEducationandEngagement.com

Read our manuscript "A phase 1, double-blind, placebo-controlled trial of sevasemten (EDG-5506), a selective modulator of fast skeletal muscle contraction, in healthy volunteers and adults with Becker muscular dystrophy," featured in Muscle & Nerve, here: edgewisetx.com/science-pipeli…

We’re headed to Las Vegas for Parent Project Muscular Dystrophy (PPMD)'s Annual Conference! Come see us at our booth, schedule a 1:1 time to meet with one of our team members, or hear about our current trials during the "Therapies that Slow Progression" & "Becker Research Breakout" panels on June 21.

Today we reported positive results on our sevasemten program for Becker and Duchenne muscular dystrophies. See our press release to learn more: investors.edgewisetx.com/news/news-deta… #Becker #Duchenne

We were recently featured in the EMJ Reviews for our symposium presentation, "Spotlight on Becker Muscular Dystrophy: Understanding the Lived Experience of Becker and Clinical Advancements with a Novel Agent," at the #MDAConference. Read it here: emjreviews.com/neurology/symp…

"Liberty, when it begins to take root, is a plant of rapid growth." - George Washington Today we celebrate freedom and liberty. Happy 4th of July from the Edgewise team! #IndependenceDay

At Edgewise, we’re always listening to the patients we serve. Their courage is what fuels passion–propelling us toward our vision of improving the lives of patients and families suffering from serious muscle diseases. Learn more about our company values: edgewisetx.com/company/

ICYMI: EMJ Reviews recently published our infographic, which presents valuable insights on #Becker disease, including the diagnostic journey, the NSAA functional assessment, & key considerations for those living with the condition. View our infographic: bit.ly/3IBoZIM

Patient, advocate, author, @LindsayLuvDAvis, lives with #HCM, a common genetic heart disease, that affects approx 1 in 500 people. Her story illustrates the reality of living with an ‘invisible illness.” Read (and watch!) her patient story here: edgewisetx.com/patients-famil…

#DYK the heart counts as a muscle? Our clinical advancements go beyond #Becker and #Duchenne–we’re also targeting #HypertrophicCardiomyopathy, also known as #HCM. Learn more about our CIRRUS-HCM clinical trial here: edgewisetx.com/science-pipeli…